Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Comments on sunscreen ingredients' environmental impact

This article was originally published in The Tan Sheet

Executive Summary

FDA requests comments on the potential environmental impact of sunscreen ingredients and other substances the agency may add to OTC monographs. In a 1notice prepared for the Feb. 22 Federal Register, the Center for Drug Evaluation and Research says environmental regulations require it to estimate the substances' expected introductory concentration in the aquatic environment. The notice lists ingredients not currently approved for use including: amiloxate, bemotrizinol, bisoctrizole, diethylhexyl butamido triazone, enzacamene and octyl triazone for sunscreen; climbazole, piroctone olamine and sodium shale oil sulfonate for dandruff; laxative ingredient sodium picosulfate; and triclosan for acne treatment. The notice also lists ingredients currently marketed in the U.S. through new drug applications as possible OTC monograph additions, ecamsule for sunscreen and triclosan for oral care. The sunscreen ingredients would be part of the first final monograph published for the indication. A final monograph emerged in 1999, but its publication was consistently stayed due to industry pressure, which continued since FDA issued a draft rule in August 2007 (2"The Tan Sheet" Nov. 30, 2009, In Brief). CDER will accept environmental impact comments concerning these ingredients for three months

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel